Explore 3 Stock Ideas & Industry Insights Download Free Report

Marker Therapeutics Inc

Company price
0.87 USD -0.03 ( 3.33%)
Last update at 2026-11-13T21:00:00Z
VOLUME
75584
Market Cap
19.51M

Momentum Score

…

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.87
Low
0.93
High
52 Week Price Range
0.84
Low
2.46
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Marker Therapeutics Inc is a clinical-stage immuno-oncology company developing T-cell therapies for solid tumors and hematologic malignancies. Growth drivers include clinical trial progress, regulatory approvals, manufacturing scale-up and partnerships that could support adoption of personalized cell therapies. Investors may view the company as exposure to differentiated cell therapy approaches in a large oncology market.

Key risks are clinical or regulatory setbacks, high capital and manufacturing needs, strong competition from larger oncology firms, and shareholder dilution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.90
Dividend Yield
-
Revenue TTM
3.55M
Revenue Per Share
0.19
Gross Profit TTM
-5.26M
Debt / Equity
0.39
ROE
-76.87%
Net Debt
-16.07M
ROCE
-76.74%
Diluted EPS TTM
-0.38

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -12.18M -10.68M -14.04M -29.93M -41.88M
Net income -12.16M -10.73M -8.24M -29.92M -41.87M
Selling general administrative 4.18M 4.24M 7.48M 12.82M 12.92M
Gross profit - -6.88M -7.11M 9.00M 1.24M
Reconciled depreciation - - - 3.68M 3.16M
Ebit - -10.68M -14.04M -29.95M -39.48M
Ebitda -12.44M -10.68M -11.25M -26.27M -36.32M
Depreciation and amortization - 0.00M 2.79M 3.68M 3.16M
Operating income -12.89M -11.12M -14.58M -29.95M -39.48M
Other operating expenses 12.89M 17.71M 17.89M 38.96M 40.72M
Interest expense - - - -0.02M 0.01M
Tax provision -0.02M 0.05M 0.00M - -
Interest income 0.59M 0.44M 0.45M 0.25M 0.01M
Net interest income 0.59M 0.44M 0.45M 0.25M 0.01M
Income tax expense -0.02M 0.05M 0.00M -0.02M -0.01M
Total revenue 3.55M 6.59M 3.31M 9.00M 1.24M
Total operating expenses 12.89M 4.24M 7.48M 38.96M 40.72M
Cost of revenue - 13.47M 10.42M - -
Total other income expense net 0.71M 0.44M 0.54M 0.02M -2.40M
Net income from continuing ops -12.16M -10.73M -24.50M -29.93M -41.88M
Net income applicable to common shares - - - - -41.88M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 19.07M 22.02M 17.13M 34.42M 68.14M
Other current assets 1.63M 0.48M 0.99M 2.44M 3.63M
Total liab 2.27M 3.46M 3.07M 14.82M 24.15M
Total stockholder equity 16.80M 18.56M 14.05M 19.60M 43.99M
Other current liab 0.51M 2.29M 2.11M 3.09M 5.99M
Common stock 0.02M 0.01M 0.01M 0.01M 0.08M
Capital stock 0.02M 0.01M 0.01M 0.01M 0.08M
Retained earnings -459.18M -447.02M -436.29M -428.05M -398.12M
Other assets - - - - -0.00M
Cash 16.07M 19.19M 15.11M 11.78M 42.35M
Total current liabilities 2.27M 3.46M 3.07M 7.78M 12.90M
Current deferred revenue 0.97M - - 2.50M 1.15M
Net debt -16.07M -19.19M -15.11M -4.17M -30.48M
Short term debt - - - 0.58M 0.62M
Short long term debt total - - - 7.62M 11.87M
Other stockholder equity 475.96M 465.56M 450.33M 447.64M 442.02M
Property plant equipment - - - - 22.15M
Total current assets 19.07M 22.02M 17.13M 16.62M 45.98M
Net tangible assets - - - - 43.99M
Short term investments - 19192420.81M - - -
Net receivables 1.37M 2.35M 1.03M 2.40M 0.00M
Inventory - - 0.00M - -
Accounts payable 0.79M 1.07M 0.96M 1.61M 5.14M
Non currrent assets other - - - - 2.23M
Non current assets total 0.00M 0.00M 0.00M 17.80M 22.15M
Capital lease obligations - - - 7.62M 11.87M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 18.54M -4.95M -3.13M
Change to liabilities - - - - 5.29M
Total cashflows from investing activities - - 18.66M - -3.13M
Total cash from financing activities 9.86M 14.99M 1.11M 0.20M 52.56M
Change to operating activities - - - - -0.82M
Net income -12.16M -10.73M -14.05M -29.93M -41.88M
Change in cash -2.15M 4.08M 3.33M -31.72M 22.14M
Begin period cash flow 19.19M 15.11M 11.78M 43.50M 21.35M
End period cash flow 17.04M 19.19M 15.11M 11.78M 43.50M
Total cash from operating activities -12.01M -10.91M -16.44M -26.97M -27.28M
Issuance of capital stock 9.86M 14.93M 1.15M 0.20M 52.55M
Depreciation - - - 3.68M 3.16M
Other cashflows from investing activities - - 18.66M - -
Change to account receivables 0.98M -1.32M 1.37M - 1.00M
Other cashflows from financing activities 9864478.14M 0.06M 0.09M -4.95M 0.00M
Change to netincome - - - - 5.96M
Capital expenditures 0.00M 0.00M 0.00M 4.95M 3.13M
Change in working capital -0.39M -0.42M 2.85M -5.81M 5.47M
Stock based compensation 0.54M 0.25M 0.86M 5.34M 5.96M
Other non cash items -388000.61M -11156176.84M -6.10M -0.25M 0.00M
Free cash flow -12.01M -10.91M -16.44M -31.92M -30.41M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MRKR
Marker Therapeutics Inc
-0.03
3.33%
0.87 - - 5.50 1.60 0.72 -0.22
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Marker Therapeutics Inc

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

2450 Holcombe Blvd, Houston, TX, United States, 77021

713 400 6400

5

Name Title Year Born
Mr. Peter L. Hoang MBA Pres, CEO & Director 1972
Dr. Mythili Koneru M.D., Ph.D. Chief Medical Officer 1978
Dr. Juan F. Vera M.D. Co-Founder, COO, Chief Scientific Officer & Director 1980
Mr. Michael J. Loiacono Chief Accounting Officer, Treasurer & Sec. 1966
Ms. Elizabeth Donnelly Director of Admin. NA
Mr. Edmund Cheung VP of HR NA
Dr. Nadia Agopyan Ph.D. Sr. VP of Regulatory Affairs NA
Dr. Robert Z. Florkiewicz Sr. Sr. Director of Molecular Biology & Virology NA
Dr. Juan F. Vera M.D. Co-Founder, CEO, President, Treasurer & Director 1981
Ms. Elizabeth Donnelly Director of Administration NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…